Expert Briefing on Health Care Sector Stocks - Edwards Lifesciences, Catamaran, Quest Diagnostics, Aetna, and WellPoint

Editor Note: For more information about this release, please scroll to bottom.

LONDON, September 15, 2014 /PRNewswire/ --

On Friday, September 12, 2014, the NASDAQ Composite ended at 4,567.60, down 0.53%, the Dow Jones Industrial Average finished the day 0.36% lower at 16,987.51, and the S&P 500 closed at 1,985.54, down 0.60%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 736.69, down 0.69%, while the index has advanced 7.01% in the previous three months. Investor-Edge has initiated coverage on the following equities: Edwards Lifesciences Corporation (NYSE: EW), Catamaran Corporation (NASDAQ: CTRX), Quest Diagnostics Inc. (NYSE: DGX), Aetna Inc. (NYSE: AET), and WellPoint Inc. (NYSE: WLP). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

Edwards Lifesciences Corp.'s stock declined 1.48%, to close the day at $99.68. The stock recorded a trading volume of 0.97 million shares, below its three months average volume of 1.04 million shares. The stock oscillated between $99.38 and $100.99 during the session. Over the last one month and over the past three months, Edwards Lifesciences Corp.'s shares have gained 4.17% and 27.21%, respectively. Further, the stock has surged 51.58% since the start of this year. The shares are trading above its 50-day and 200-day moving averages. Edwards Lifesciences Corp.'s 50-day moving average of $93.06 is above its 200-day moving average of $78.60. Additionally, the stock traded at a PE ratio of 38.03 and has a Relative Strength Index (RSI) of 62.81. Sign up and read the free notes on EW at:

www.Investor-Edge.com/EW-15Sep2014

On Friday, shares in Catamaran Corp. recorded a trading volume of 1.04 million shares, lower than its three months average volume of 1.21 million shares. The stock ended the day at $47.93, which was 0.10% above its previous day's closing of $47.88, and registered an intraday range of $47.75 and $48.12. Catamaran Corp.'s shares have gained 5.13% in the last one month, 11.31% in the previous three months and 0.99% on YTD basis. The stock is trading above its 50-day and 200-day moving averages of $45.65 and $45.37, respectively. Furthermore, shares of Catamaran Corp. have an RSI of 60.23. The complimentary notes on CTRX can be downloaded as in PDF format at:

www.Investor-Edge.com/CTRX-15Sep2014

Quest Diagnostics Inc.'s stock edged 0.68% lower, to close Friday's session at $62.62, after oscillating between $62.42 and $63.14. The stock recorded a trading volume of 0.71 million shares, much below its three months average volume of 1.22 million shares. Over the last one month and the previous three months, Quest Diagnostics Inc.'s shares have advanced 1.41% and 5.76%, respectively. Additionally, the stock has gained 16.96% since the beginning of this year. The stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $61.58 is above its 200-day moving average of $57.59. Further, Quest Diagnostics Inc.'s stock traded at a PE ratio of 15.83 and has an RSI of 51.18. Register for free on Investor-Edge and access the latest research on DGX at:

www.Investor-Edge.com/DGX-15Sep2014

Aetna Inc.'s stock finished Friday's session 1.78% lower at $82.20. A total of 2.29 million shares were traded, which was close to its three months average volume of 2.20 million shares. The stock moved between $82.00 and $83.76 during the session. Aetna Inc.'s shares have advanced 5.87% in the last one month and 1.56% in the previous three months. Further, from the beginning of 2014, the stock has gained an upside of 19.84%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $81.03 is greater than its 200-day moving average of $74.56. Aetna Inc.'s stock traded at a PE ratio of 13.18 and has an RSI of 53.36. The complete research on AET is available for free at:

www.Investor-Edge.com/AET-15Sep2014

On Friday, shares in WellPoint Inc. traded between $118.19 and $120.17 before ending the session 1.11% lower at $118.62. The stock reported a trading volume of 1.21 million shares, below its three months average volume of 1.72 million shares. Shares of the company traded at a PE ratio of 14.43. WellPoint Inc.'s shares have advanced 5.46% in the last one month, 10.98% in the previous three months and 28.39% on YTD basis. The shares are trading above its 50-day and 200-day moving averages of $113.42 and $100.39, respectively. Moreover, shares of WellPoint Inc. have an RSI of 60.93. Free in depth research on WLP is available at:

www.Investor-Edge.com/WLP-15Sep2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.